ANZERVA-1 MG TABLET | ANASTROZOLE 1 MG Aromatase Inhibitor
ANZERVA-1 MG TABLET contains ANASTROZOLE 1 MG, an aromatase inhibitor used in physician-directed hormonal therapy for selected hormone receptor-positive breast cancer treatment.
ANZERVA-1 MG TABLET – ANASTROZOLE 1 MG
Product Summary
ANZERVA-1 MG TABLET contains ANASTROZOLE 1 MG, a non-steroidal aromatase inhibitor used as part of physician-directed hormonal therapy. It is primarily prescribed for postmenopausal women with certain hormone receptor-positive breast cancers, including early, locally advanced, or metastatic disease. Its therapeutic action is based on reducing estrogen production in the body.
Product Full Description
ANZERVA-1 MG TABLET contains ANASTROZOLE 1 MG, an aromatase inhibitor used in endocrine treatment protocols.
Anastrozole works by reducing the conversion of androgens into estrogens through inhibition of the aromatase enzyme.
Lower estrogen availability can reduce hormonal stimulation of estrogen-sensitive breast cancer cells.
The medicine is administered orally and is generally taken once daily when prescribed.
Treatment should be individualized according to the patient's diagnosis, menopausal status, and clinical response.
ANZERVA-1 MG TABLET should be used only under appropriate medical supervision.
Usage Instructions
Take ANZERVA-1 MG TABLET exactly as prescribed by your healthcare professional.
The standard labeled dose of anastrozole is 1 mg once daily.
Swallow the tablet whole with water.
It may be taken with or without food.
Take it at approximately the same time each day to maintain a consistent treatment routine.
Do not change the dose or discontinue treatment without consulting your healthcare professional.
Medicinal Advantages
Provides estrogen-lowering activity through aromatase inhibition.
Used in adjuvant treatment of certain hormone receptor-positive early breast cancers in postmenopausal women.
Used as first-line hormonal therapy for certain locally advanced or metastatic breast cancers in postmenopausal women.
May be used for advanced breast cancer following progression after tamoxifen therapy in appropriate patients.
Offers convenient once-daily oral administration.
Mechanism of Action
ANZERVA-1 MG TABLET contains ANASTROZOLE, which selectively inhibits the aromatase enzyme. Aromatase converts androgens into estrogen in peripheral tissues. By inhibiting this conversion, anastrozole substantially lowers circulating estrogen levels. In hormone-sensitive breast cancer, reducing estrogen availability can decrease hormonal stimulation of estrogen-dependent tumor cells.
Off-Label Uses
Anastrozole may be considered by specialists for certain clinical applications outside its labeled breast-cancer indications. Such use should be based on appropriate medical evidence and individualized specialist assessment.
It should not be promoted for non-approved uses such as bodybuilding, performance enhancement, or self-directed hormone manipulation without medical supervision.
Expert Advice
ANZERVA-1 MG TABLET should be used under the supervision of an oncologist or other qualified healthcare professional.
Confirm that the treatment is appropriate for the patient's menopausal and hormone-receptor status.
Follow the prescribed once-daily regimen consistently.
Discuss all other medicines and supplements with the treating healthcare professional.
Long-term treatment may require clinical monitoring, including assessment of bone health and other relevant parameters. Current prescribing information notes that reductions in bone mineral density and increases in cholesterol can occur during anastrozole treatment.
Precautions
1. Pregnancy and Premenopausal Use
Anastrozole is not intended for routine use during pregnancy and is primarily indicated for postmenopausal women in the labeled breast-cancer indications. Appropriate medical assessment is required before treatment.
2. Bone Health Monitoring
Anastrozole can reduce bone mineral density. Healthcare professionals may therefore consider bone-health assessment and appropriate monitoring during longer-term therapy.
3. Cardiovascular Considerations
Patients with pre-existing ischemic heart disease require appropriate medical assessment because prescribing information identifies cardiovascular considerations with anastrozole therapy.
4. Cholesterol Monitoring
Anastrozole treatment may increase total cholesterol, so lipid monitoring may be considered where clinically appropriate.
Storage Conditions
Store ANZERVA-1 MG TABLET according to the temperature specified on its packaging.
Many anastrozole 1 mg tablet labels specify controlled room-temperature storage around 20–25°C.
Keep the tablets protected from excessive heat and moisture.
Keep the medicine in its original packaging until use.
Keep out of reach of children.
Frequently Asked Questions (FAQs)
1. What is ANZERVA-1 MG TABLET?
ANZERVA-1 MG TABLET contains ANASTROZOLE 1 MG, an aromatase inhibitor used in selected hormone-based breast-cancer treatment plans.
2. What drug class does ANASTROZOLE belong to?
ANASTROZOLE belongs to the aromatase inhibitor class of medicines.
3. How does ANZERVA-1 MG TABLET work?
It inhibits aromatase, reducing the body's production of estrogen and thereby reducing estrogen stimulation of hormone-sensitive breast cancer cells.
4. What is the usual labeled dose?
The labeled dose for anastrozole is one 1 mg tablet once daily, although treatment should always follow the prescribing clinician's instructions.
5. Can ANZERVA-1 MG TABLET be taken with food?
Yes. Anastrozole tablets can generally be taken with or without food.
6. Is ANZERVA-1 MG TABLET a prescription medicine?
Yes. Anastrozole 1 mg tablets are prescription medicines and should be used under appropriate medical supervision.
7. Who commonly receives anastrozole treatment?
Its labeled indications include postmenopausal women with certain hormone receptor-positive early, locally advanced, or metastatic breast cancers, as well as selected advanced breast cancer following tamoxifen therapy.
Suggested Product Tags
ANZERVA-1 MG TABLET, ANASTROZOLE 1 MG, ANASTROZOLE TABLET, Aromatase Inhibitor, Hormonal Therapy, Breast Cancer Treatment, Oncology Medicine, Estrogen Inhibitor, Postmenopausal Breast Cancer, Oral Oncology Medicine, Prescription Medicine
